SELLAS Life Sciences stock soars 240% on positive cancer trial
SELLAS Life Sciences (NASDAQ:SLS) shares rose 240% after reporting positive Phase 3 trial results for its cancer vaccine, GPS. The trial met its primary endpoint, showing a 41% reduction in death risk and improved median survival. The company plans to discuss an accelerated FDA filing strategy. GPS was well-tolerated with mild to moderate side effects.
How this was made
The 30-second read
Why it matters
The disclosed OS benefit (hazard ratio 0.59, p-value 0.035) plus a stated intent to pursue an accelerated filing strategy and prepare a BLA in 1H 2027 are likely to increase perceived regulatory and commercialization probability, supporting a higher valuation multiple.
Market read
Traders can act on a fresh pivotal-trial catalyst with explicit regulatory next steps, which typically changes near-term positioning and options pricing for biotech risk.
What to watch
The article does not provide details on secondary endpoints, subgroup effects, or manufacturing/commercial readiness, which can materially affect valuation even after OS success.
Background
SELLAS is advancing galinpepimut-S (GPS) in acute myeloid leukemia; the REGAL Phase 3 trial is described as pivotal and focused on maintenance monotherapy in patients in second or later complete remission who cannot undergo allogeneic stem cell transplantation.
Ticker impact
SELLAS shares surged after announcing positive topline Phase 3 REGAL results for galinpepimut-S, including OS benefit and FDA accelerated filing plans.
Likely upward bias as markets price higher odds of accelerated approval, with potential pullbacks on dilution/valuation concerns and as secondary endpoints and safety details mature.
The article reports primary endpoint success (OS, hazard ratio, p-value) plus a stated plan to meet FDA and prepare a BLA in 1H 2027, which are direct catalysts for biotech risk-reward repricing.
Market effects
Reinforces risk-on sentiment for AML immunotherapy vaccine approaches and can lift peer sentiment around immunotherapeutic strategies, though impact is company-specific.
Limited broader regional spillover expected beyond US biotech sentiment given the single-name catalyst.
Moderate global relevance for oncology trial read-through, but the trading signal is primarily US-listed biotech-specific.
Counterpoint
A single topline primary endpoint can be over-discounted; secondary endpoints, durability, and any later safety signals could temper the initial enthusiasm.
Key entities
- companySELLAS Life Sciences Group
NASDAQ-listed biotech whose REGAL Phase 3 topline results for galinpepimut-S drove a sharp share surge.
- productGalinpepimut-S (GPS)
Immunotherapeutic cancer vaccine evaluated as maintenance monotherapy in the REGAL trial.
- regulatorU.S. Food and Drug Administration (FDA)
Planned meeting to discuss accelerated filing strategy for a potential BLA submission.


